

GANDHAR OIL REFINERY (INDIA) LIMITED

22-11-2023 to 24-11-2023

Industry: Specialty Chemicals
Recommendation: Subscribe for Listing Gains

Price Band: ₹ 160 - 169 Post Implied Market Cap: ₹ 1,582 - 1,654 Cr

Key Data

Issue Size (₹ Cr)	501
, ,	
Fresh (₹)	302
OFS (₹)	199
No of shares offered	30,631,910 -
	29,626,732
Face Value (₹ /share)	2
Rid Lot	88

About the Company

Gandhar Oil Refinery (India) Limited, established in 1992, is a prominent manufacturer of white oils, focusing on personal care, healthcare, lubricants, and insulating oils under the "Divyol" brand. As of June 30, 2023, it operates three manufacturing facilities in India and the UAE, with a total capacity of 522,403 kL. Gandhar is India's largest white oil manufacturer by revenue in FY2023 and among the top five globally by market share in 2022. With a diverse customer base of 3,558, including major companies like P&G, Unilever, and Marico, their products are sold in over 100 countries. The company also distributes automotive oil products domestically through 282 distributors and 27 depots, including four company-operated ones.

Indicative Timetable

Activity	On or about
Finalisation of Basis of Allotment	30-11-2023
Refunds/Unblocking ASBA Fund	01-12-2023
Credit of equity shares to DP A/c	04-12-2023
Trading commences	05-12-2023

Investment Rationale

- Leading market share of the Indian white oils market with significant overseas sales, focused on the consumer and healthcare end-industries: Gandhar is India's leading white oil manufacturer by revenue in FY2023, ranking among the top five globally by market share in 2022. With a diverse portfolio of over 440 products, they play a crucial role in various consumer and healthcare industries, including cosmetics, skincare, medicines, lubricants, and processing oils. Their focus on the consumer and healthcare sectors is evident in the Personal Care, Healthcare, and Performance Oils division. Operating in over 100 countries across Asia-Pacific, Europe, Africa, and the Americas, Gandhar has a significant global presence as of June 30, 2023.
- Extensive and diversified customer base and a supplier base comprised of leading oil companies with competitive pricing: Gandhar maintains strong customer loyalty with repeat order percentages of 83.74%, 69.11%, 68.86%, and 66.37% for the quarters ending June 30, 2023, and fiscal years 2023, 2022, and 2021, respectively. They establish annual agreements, some with price pass-through provisions, with certain customers. The company predominantly sources raw materials from South Korea and the Gulf Co-operation Council Region, relying on key suppliers such as SK Lubricants, S-Oil, GS Caltex, and other global base oil suppliers.
- Strategically located manufacturing facilities and in-house R&D capabilities: Gandhar operates three manufacturing facilities with a total annual production capacity of approximately 522,403 kL as of June 30, 2023. The Taloja Plant, strategically located near Mumbai and JNPT ports with excellent road and rail connectivity, enhances logistical efficiency. Additionally, the company conducts research and development activities at their Silvassa manufacturing facility to support their manufacturing operations.
- Resilient, flexible, and scalable business model with prudent risk management framework: With three decades of experience in specialty oils, Gandhar has expanded operations, emphasizing efficiency and cost reduction. In the capital-intensive and complex specialty oil industry, they prioritize risk mitigation through strategies such as minimizing price and foreign exchange risks, efficient inventory management, and prudent capital, credit, and liquidity management. Diversification in their customer base safeguards against concentration risk. As of September 30, 2023, they maintain substantial liquidity with working capital facilities of around ₹1,966.38 crore to support their business operations.

Shareholding (No. of shares)

Pre-Issue Post Issue (Lower price band)	8,00,00,000
Post Issue (Lower price band)	9,88,75,000
Post Issue (Higher price band)	9.78.69.822

Shareholding Pattern

Promoters:	
Pre Issue	42.49%
Post Issue	32.43%
Promoter Group:	
Pre Issue	45.01%
Post Issue	32.20%
Public - Other Selling S/h:	
Pre Issue	6.25%
Post Issue	0.00%
Public -Others:	

Issue Breakup

Pre Issue

Post Issue

OID	_
QIB	50%
NIB	
D-4-:I	15%
Retail	35%

Risk

6.25%

35.37%

- Dependency on limited supplier for a significant portion of raw material.
- Fluctuation in the price of raw material.

Other Details

BRLMs: Nuvama Wealth, ICICI Securities **Registrar:** Link Intime India Pvt. Ltd. **Listing:** BSE & NSE

MView

We believe Gandhar Oil IPO offers gives investors an opportunity to invest in the largest manufacturer of white oils company which exports over 100 countries. We think as a well-established player in white oil, a company holding a dominant market share with an extensive product portfolio of 440 products, caters to diverse consumers and healthcare worldwide. We also believe with the evidence of repeat order percentage exceeding ~80% underscore a stable customer relationship and competitive pricing. The 3 decades of experience in the specialty oils sector reflect a resilient, flexible and scalable business model with emphasis on efficiency, cost reduction, and risk mitigation strategies that showcase a prudent risk management framework. By looking at the financials the company has shown a strong growth between fiscal 2022 and 2023 with a 59.4%/15.13% in revenue from operations and 63%/30% in net profit. On Valuation parse at upper price band of ₹ 169/-, the issue is asking for a Market Cap of ₹ 1654 Cr. Based on annualized FY24 earnings and fully diluted post-IPO paid-up capital, the company is asking a P/E of 7.62x which seems the valuations are reasonable when compared to its industry peers which are trading above ~17x on average. Giving a good room of listing gains due to valuation gap between listed and Gandhar Oil. We believe the company has created a niche place in white oil and serving diversified industrial users which gives this company an edge against the peers in the segment. Hence, considering all the parameters, we are recommending investors to "SUBSCRIBE" the issue for listing only.

Research Analyst

Rajan Shinde

Rajan.shinde@mehtagroup.in 022-61507142





CONSOLIDATED FINANCIAL TABLES

BASIC FINANCIAL DETAILS				
	As at June' 30	As at March' 31		
Particulars ₹ (in Cr)	2023 (03)	2023	2021	
Equity Share Capital	16	16	16	16
Reserve	753.79	709.30	525.12	428.83
Non-Controlling Interest	41.00	34.91	19.58	-
Net Worth	810.79	760.21	560.71	444.83
Revenue From Operations	1,070.34	4,079.44	3,543.37	2,221.00
Revenue Growth %	-	15.1%	59.5%	-
EBITDA	84.06	316.62	245.97	138.77
EBITDA Margin (%)	7.85%	7.76%	6.97%	6.25%
Profit Before Tax	67.14	270.95	225.23	120.28
Net Profit for the Period	54.28	213.18	163.58	100.32
Net Profit Margin (%) as stated	5.07%	5.20%	4.58%	4.47%
EPS (₹)	5.6	23.77	18.42	12.54
RONW(%)	6.91%	32.38%	32.54%	24.77%
NAV (₹)	101.35	95.03	70.09	55.6

Source: Company RHP

COMPARISON WITH LISTED PEERS ₹ (in Cr)								
Companies	Consolidated/ Standalone	Mcap (in Cr)	FV	Revenue fron Operation FY 2023 (In Cr)	EPS	NAV	P/E	RONW
Gandhar Oil Refinery (India) Ltd	Consolidated (Annualised FY 2024)	1654	2	4,079.44	22.18	161.2	7.62	32.28%
Savita Oil Technologies Ltd	Consolidated	2,243	2	3,630.44	32.66	209.7	13.5	16.68%
Apar Industries Ltd	Consolidated	21,456	10	14,352.15	166.64	584.39	27.5	32.28%
Panama Petrochem Ltd	Consolidated	1,898	2	2,248.72	38.51	157.39	9.8	27.08%
Galaxy Surfactants Ltd	Consolidated	10,025	10	4,445.24	107.46	530.97	28.7	22.04%
Privi Specialty Chemicals Ltd	Consolidated	4,989	10	1,607.82	5.45	213.88	224	2.57%
Rossari Biotech Ltd	Consolidated	3,913	2	1,655.88	19.46	165.92	33.5	12.47%
Fairchem Organics Ltd	Consolidated	1,542	10	648.04	33.41	199.11	53.4	17.70%

Date as on 31st March 2023, Cline Mcap, PE calculated as on 22-11-2023 Gandhar Oil India Ltd, Revenue EPS/PE, NAV calculated on annualised basis post money



This Report is published by Mehta Equities Limited (hereinafter referred to as "MEL") for registered client circulation only. MEL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH00000552. MEL is a registered broker with the Securities & Exchange Board of India (SEBI) and registered with National Stock Exchange of India Limited and BSE Limited in cash and derivatives segments, Multi Commodity Exchange of India (MCX), National Commodity & Derivatives Exchange Ltd. (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL), is registered with SEBI for providing PMS services and distribute third party PMS product and also member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

MEL a "Research Entity" under SEBI (Research Analyst) Regulations 2014 has independent research teams working with a Chinese wall rule with other business divisions of MEL as mentioned above.

MEL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. MEL, its associates or Research analyst or his relatives do not hold any financial interest in the subject company. MEL or its associates or Research analysts do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. MEL or its associates or Research Analyst or his relatives do not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report.

MEL or its associates or Research analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Research analyst during the past twelve months. MEL or its associates have not received any compensation or other benefits from the company covered by Research analyst or third party in connection with the research report. Research Analyst has not served as an officer, director or employee of Subject Company and MEL / Research analyst has not been engaged in market making activity of the subject company.

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. MEL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader. This research has been prepared for the general use of the clients of MEL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MEL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MEL & its group companies to registration or licensing requirements within such jurisdictions.

The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. MEL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MEL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This information is subject to change without any prior notice. MEL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, MEL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.

Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of MEL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither MEL, nor its directors, employees, or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report.

Analyst Certification: Research Analyst the author of this report, hereby certify that the views expressed in this research report accurately reflects my personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the Research analyst was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The Research analyst is principally be responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

Msearch's Recommendation (Absolute Performance)
Buy: > 20% within the next 12 Months
Accumulate: 5% to 20% within the next 12 Months
Sell: < -20% within the next 12 Months

MEHTA EQUITIES LTD

BSE: - Membership Clearing No. 122 - SEBI Regn. No. INB010683856, NSE: - Membership Clearing No. 13512-SEBI Regn. No. INB231351231, NSE FO SEBI Regn. No. INF231351231, CIN No: U65990MH1994PLC078478
MSEI: - Membership Clearing No. 51800 - SEBI Regn. No. INB261351234 SEBI registered RA Reg No INH000000552
Mehta Equities Limited, 903, 9th Floor, Lodha Supremus, Dr.E.Moses Road, Worli Naka, Worli, Mumbai 400 018, India

Tel: +91 22 6150 7101, Fax: +91 22 6150 7102 Email: info@mehtagroup.in, Website: www.mehtagroup.in Compliance Officer: Prakash Joshi

Email Id: compliance@mehtagroup.in
Phone No +91 22 61507180

For grievance redressal contact Customer Care Team Email: help.kyc@mehtagroup.in Phone: + 91 22 61507154